Cerebrospinal fluid Aβ40 is similarly reduced in patients with Frontotemporal Lobar Degeneration and Alzheimer's Disease

Journal of the Neurological Sciences

Volumn 358, Issue 1-2, 2015, Pages 308-316

  Baldeiras, Inês ^a,b,c   Santana, Isabel ^a,b,c   Leitão, Maria João ^a,b   Ribeiro, Maria Helena ^a,b,c   Pascoal, Rui ^a   Duro, Diana ^a   Lemos, Raquel ^a   Santiago, Beatriz ^a   Almeida, Maria Rosário ^b   Oliveira, Catarina Resende ^a,b,c  

^a CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Ab40; Biomarkers; Cerebrospinal fluid; Diagnostic accuracy; Frontotemporal lobar degeneration, Alzheimer's Disease

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; TAU PROTEIN; AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; PEPTIDE FRAGMENT;

ADULT; ALLELE; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE MARKER; FEMALE; FRONTAL VARIANT FRONTOTEMPORAL DEMENTIA; FRONTOTEMPORAL DEMENTIA; GENE MUTATION; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; AGED; CEREBROSPINAL FLUID; SENSITIVITY AND SPECIFICITY;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOMARKERS; FEMALE; FRONTOTEMPORAL LOBAR DEGENERATION; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; SENSITIVITY AND SPECIFICITY;

EID: 84956762726     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2015.09.022     Document Type: Article

References (95)

1. S. Al-Sarraj, A. King, C. Troakes, B. Smith, S. Maekawa, I. Bodi, B. Rogelj, A. Al-Chalabi, T. Hortobagyi, C.E. Shaw, p62 positive, TDP-43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72-linked FTLD and MND/ALS, Acta Neuropathol. 122 (2011) 691-702.
2. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 4 rd ed, American Psychiatric Association, Washington, DC, 1994.
3. I. Baldeiras, M.H. Ribeiro, P. Pacheco, A. Machado, I. Santana, L. Cunha, C.R. Oliveira, Diagnostic value of CSF protein profile in a Portuguese population of sCJD patients, J. Neurol. 256 (2009) 1540-1550.
4. L. Berg, Clinical dementia rating (CDR), Psychopharmacol. Bull. 24 (1988) 637-639.
5. H. Bian, J.C. Van Swieten, S. Leight, L. Massimo, E. Wood, M. Forman, P. Moore, I. de Koning, C.M. Clark, S. Rosso, J. Trojanowski, V.M.-Y. Lee, M. Grossman, CSF bio-markers in frontotemporal lobar degeneration with known pathology, Neurology 70 (2008) 1827-1835.
6. M. Bibl, B. Mollenhauer, P. Lewczuk, H. Esselmann, S. Wolf, M. Otto, J. Kornhuber, E. Rüther, J. Wiltfang, Cerebrospinal fluid Tau, p-Tau 181 and Amyloid-β38/40/42 in frontotemporal dementias and primary progressive aphasias, Dement. Geriatr. Cogn. Disord. 31 (2011) 37-44.
7. M. Bibl, M. Gallus, V. Welge, H. Esselmann, S. Wolf, E. Rüther, J. Wiltfang, Cerebrospi-nal fluid Ab42 is decreased in Alzheimer's, but not in frontotemporal dementia, J. Neural Transm. 119 (2012) 805-813.
8. M. Bibl, B. Mollenhauer, S. Wolf, H. Esselmann, P. Lewczuk, J. Kornhuber, J. Wiltfang, Reduced CSF carboxyterminally truncated Ab peptides in frontotemporal lobe degenerations, J. Neural Transm. 114 (2007) 621-628.
9. E.H. Bigio, M. Mishra, K.J. Hatanpaa, C.L. White 3rd, N. Johnson, A. Rademaker, B.B. Weitner, H.X. Deng, S.D. Dubner, S. Weintraub, M. Mesulam, TDP-43 pathology in primary progressive aphasia and frontotemporal dementia with pathologic Alzheimer disease, Acta Neuropathol. 120 (2010) 43-54.
10. K. Blennow, H. Hampel, M. Weiner, H. Zetterberg, Cerebrospinal fluid and plasma biomarkers in Alzheimer's disease, Nat. Rev. Neurol. 6 (2010) 131-144.
11. B.F. Boeve, Links between frontotemporal lobar degeneration, corticobasal degeneration, progressive supranuclear palsy, and amyotrophic lateral sclerosis, Alzheimer Dis. Assoc. Disord. 21 (2007) S31-S38.
12. B. Borroni, A. Benussi, S. Archetti, D. Galimberti, L. Parnetti, B. Nacmias, S.E. SorbiS, A. Padovani, CSF p-tau181/tau ratio as biomarker for TDP pathology in frontotemporal dementia, Amyotroph. Lateral Scler. Frontotemporal Degener 16 (2015) 86-91.
13. B. Borroni, C. Cerini, S. Archetti, E. Premi, M. Cosseddu, M. Ferrari, G. Bellelli, R. Gasparotti, L. Caimi, M.D. Luca, A. Padovani, Cerebrospinal fluid tau infrontotemporal lobar degeneration: clinical, neuroimaging, and prognostic correlates, J. Alzheimers Dis. 23 (2010) 505-512.
14. H. Brunnstrom, N. Rawshani, H. Zetterberg, K. Blennow, L. Minthon, U. Passant, E. Englund, Cerebrospinal fluid biomarker results in relation to neuropathological dementia diagnosis, Alzheimers Dement. 6 (2010) 104-109.
15. R. Crook, J. Hardy, K. Duff, Single-day apolipoprotein E genotyping, J. Neurosci. Methods 53 (1994) 125-127.
16. J.L. Cummings, The neuropsychiatric inventory: assessing psychopathology in dementia patients, Neurology 48 (1997) 10-16.
17. C. Davatzikos, P. Bhatt, L.M. Shaw, K.N. Batmanghelich, J.Q. Trojanowski, Prediction of MCI to AD conversion, via MRI, CSF biomarkers, and pattern classification, Neurobiol. Aging 32 (2011) 2322.e.19-2322.e.27.
18. B. Dubois, H.H. Feldman, C. Jacova, S.T. Dekosky, P. Barberger-Gateau, J. Cummings, A. Delacourte, D. Galasko, S. Gauthier, G. Jicha, K. Meguro, J. O'brien, F. Pasquier, P. Robert, M. Rossor, S. Salloway, Y. Stern, P.J. Visser, P. Scheltens, Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria, Lancet Neurol. 6 (2007) 734-746.
19. B. Dubois, H.H. Feldman, C. Jacova, H. Hampel, J.L. Molinuevo, K. Blennow, S.T. DeKosky, S. Gauthier, D. Selkoe, R. Bateman, S. Cappa, S. Crutch, S. Engelborghs, G.B. Frisoni, N.C. Fox, D. Galasko, M.O. Habert, G.A. Jicha, A. Nordberg, F. Pasquier, G. Rabinovici, P. Robert, C. Rowe, S. Salloway, M. Sarazin, S. Epelbaum, L.C. de Souza, B. Vellas, P.J. Visser, L. Schneider, Y. Stern, P. Scheltens, J. Cummings, Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria, Lancet Neurol. 13 (2014) 614-629.
20. M. Ewers, N. Mattsson, L. Minthon, J.L. Molinuevo, A. Antonell, J. Popp, F. Jessen, S.K. Herukka, H. Soininen, W. Maetzler, T. Leyhe, K. Bürger, M. Taniguchi, K. Urakami, S. Lista, B. Dubois, K. Blennow, H. Hampel, CSF biomarkers for the differential diagnosis of Alzheimer's disease. A large-scale international multicenter study, Alzheimers Dement. (2015), http://dx.doi.org/10.1016/j.jalz.2014.12.006.
21. H. Engler, A.F. Santillo, S.X. Wang, M. Lindau, I. Savitcheva, A. Nordberg, L. Lannfelt, B. Långström, L. Kilander, In vivo amyloid imaging with PET in frontotemporal dementia, Eur. J. Nucl. Med. Mol. Imaging 35 (2008) 100-106.
22. M.A.S. Fernandes, C.R. Oliveira, L.M.V. Oliveira, A.J.A. Nogueira, B. Santiago, I. Santana, Apolipoprotein E e4 is a risk factor for Alzheimer's disease: the central region of Portugal (Coimbra) as a case study, Eur. Neurol. 42 (1999) 183-184.
23. M.F. Folstein, S.E. Folstein, P.R. McHugh, Mini-mental state: a practical method for grading the cognitive state of patients for the clinician, J. Psychiatry Res. 12 (1975) 189-198.
24. M.S. Forman, J. Farmer, J.K. Johnson, C.M. Clark, S.E. Arnold, H.B. Coslett, A. Chatterjee, H.I. Hurtig, J.H. Karlawish, H.J. Rosen, V. Van D, V.M. Lee, B.L. Miller, J.Q. Trojanowski, M. Grossman, Frontotemporal dementia: clinicopathological correlations, Ann. Neurol. 59 (2006) 952-962.
25. A. Gabelle, S. Roche, C. Gény, K. Bennys, P. Labauge, Y. Tholance, I. Quadrio, L. Tiers, B. Gor, J. Boulanghien, C. Chaulet, A. Vighetto, C. Bj, P. Krolak-Salmon, A. Perret-Liaudet, J. Touchon, S. Lehmann, Decreased sAβPPβ, Aβ38, and Aβ40 cerebrospinal fluid levels in frontotemporal dementia, J. Alzheimers Dis. 26 (2011) 553-563.
26. I. Gelinas, L. Gauthier, M. McIntyre, S. Gauthier, Development of a functional measure for persons with Alzheimer's Disease: the disability assessment for dementia scale, Am. J. Occup. Ther. 53 (1999) 471-481.
27. C. Goldsbury, M.M. Mocanu, E. Thies, C. Kaether, C. Haass, P. Keller, J. Biernat, E. Mandelkow, E.M. Mandelkow, Inhibition of APP trafficking by tau protein does not increase the generation of amyloid-beta peptides, Traffic 7 (2006) 873-888.
28. M.L. Gorno-Tempini, N.F. Dronkers, K.P. Rankin, J.M. Ogar, L. Phengrasamy, H.J. Rosen, J.K. Johnson, M.W. Weiner, B.L. Miller, Cognition and anatomy in three variants of primary progressive aphasia, Ann. Neurol. 55 (2004) 335-346.
29. A.J.E. Green, R.J. Harvey, E.J. Thompson, M.N. Rossor, Increased tau in the cerebrospi-nal fluid of patients with frontotemporal dementia and Alzheimer's disease, Neurosci. Lett. 259 (1999) 133-135.
30. M. Grossman, J. Farmer, S. Leight, M. Work, P. Moore, V. Van Deerlin, D. Pratico, C.M. Clark, H. Branch Coslett, A. Chatterjee, J. Gee, J.Q. Trojanowski, V. Lee, Cerebrospinal fluid profile inFrontotemporal dementia and Alzheimer's Disease, Ann. Neurol. 57 (2005) 721-729.
31. M. Guerreiro, Contribution of neuropsychology to the study of dementias, (Ph.D. thesis) Faculty of Medicine of Lisbon, Lisbon, Portugal, 1988.
32. M. Guerreiro, S. Fonseca, J. Barreto, Escalas e testes na demência, Grupo de Estudos de Envelhecimento Cerebral e Demência (2003) 33-49.
33. M. Guerreiro, A.P. Silva, M.A. Botelho, Avaliação breve do estado mental: escalas e testes na demência, Grupo de Estudos de Envelhecimento Cerebral e Demência (2003) 27-32.
34. J.A. Hanley, B.J. McNeil, A method of comparing the areas under receiver operating characteristic curves, Radiology 148 (1983) 839-843.
35. O. Hansson, H. Zetterberg, P. Buchhave, E. Londos, K. Blennow, L. Minthon, Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study, Lancet Neurol. 5 (2006) 228-234.
36. J. Hertze, L. Minthon, H. Zetterberg, E. Vanmechelen, K. Blennow, O. Hansson, Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical follow-up study of 4.7 years, J. Alzheimers Dis. 21 (2010) 1119-1128.
37. J.R. Hodges, K. Patterson, Semantic dementia: a unique clinicopathological syndrome, Lancet Neurol. 6 (2007) 1004-1014.
38. W.T. Hu, C. McMillan, D. Libon, S. Leight, M. Forman, V.M.-Y. Lee, J.Q. Trojanowski, M. Grossman, Multimodal predictors for Alzheimer disease in nonfluent primary progressive aphasia, Neurology 75 (2010) 595-602.
39. K. Iqbal, F. Liu, C.X. Gong, I. Grundke-Iqbal, Tau in Alzheimer disease and related tauopathies, Curr. Alzheimer Res. 7 (2010) 656-664.
40. D.J. Irwin, N.J. Cairns, M. Grossman, C.T. McMillan, E.B. Lee, V.M. Van Deerlin, V.M. Lee, J.Q. Trojanowski, Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine, Acta Neuropathol. 129 (2015) 469-491.
41. K.A. Jellinger, Recent advances in our understanding of neurodeneration, J. Neural Transm. 116 (2009) 1111-1162.
42. J.K. Johnson, E. Head, R. Kim, A. Starr, C.W. Cotman, Clinical and pathological evidence for a frontal variant of Alzheimer's disease, Arch. Neurol. 56 (1999) 1233-1239.
43. A. Kämäläinen, S.K. Herukka, P. Hartikainen, S. Helisalmi, V. Moilanen, A. Knuuttila, L. Jansson, P.J. Tienari, A.M. Remes, Cerebrospinal fluid biomarkers for Alzheimer's disease in patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis with the C9ORF72 repeat expansion, Dement. Geriatr. Cogn. Disord. 39 (2015) 287-293.
44. E. Kapaki, G.P. Paraskevas, S.G. Papageorgiou, A. Bonakis, N. Kalfakis, I. Zalonis, D. Vassilopoulos, Diagnostic value of CSF biomarker profile in frontotemporal lobar degeneration, Alzheimer Dis. Assoc. Disord. 22 (2008) 47-53.
45. A. Kertesz, P. Martinez-Lage, W. Davidson, D.G. Munoz, The corticobasal degeneration syndrome overlaps progressive aphasia and frontotemporal dementia, Neurology 55 (2000) 1368-1375.
46. A. Kertesz, P. McMonagle, M. Blair, W. Davidson, D.G. Munoz, The evolution and pathology of frontotemporal dementia, Brain 128 (2005) 1996-2005.
47. E.L.G.E. Koedam, A.E. van der Vlies, W.M. van der Flier, N.A. Verwey, T. Koene, P. Scheltens, M.A. Blankenstein, Y.A.L. Pijnenburg, Cognitive correlates of cerebrospinal fluid biomarkers in frontotemporal dementia, Alzheimers Dement. 9 (2013) 269-275.
48. O. Leitão, A. Nina, Escalas e testes na demência, Grupo de Estudos de Envelhecimento Cerebral e Demência, 2003 67-86.
49. O. Leitão, Escalas e testes na demência, Grupo de Estudos de Envelhecimento Cerebral e Demência, 2008 107-110.
50. P. Lewczuk, H. Esselmann, M. Otto, J.M. Maler, A.W. Henkel, M.K. Henkel, O. Eikenberg, C. Antz, W.-R. Krause, U. do Reulbach, J. Kornhuber, J. Wiltfang, Neuro-chemical diagnosis of Alzheimer's dementia by CSF Aβ42, Aβ42/Aβ40 ratio and total tau, Neurobiol. Aging 25 (2004) 273-281.
51. C. Lomen-Hoerth, T. Anderson, B. Miller, The overlap of amyotrophic lateral sclerosis and frontotemporal dementia, Neurology 59 (2002) 1077-1079.
52. D.M. Mann, A.M. McDonagh, S.M. Pickering-Brown, H. Kowa, T. Iwatsubo, Amyloid beta protein deposition in patients with frontotemporal lobar degeneration: relationship to age and apolipoprotein E genotype, Neurosci. Lett. 304 (2001) 161-164.
53. N. Mattsson, U. Andreasson, S. Persson, et al., The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers, Alzheimers Dement. 7 (2011) 386-395.
54. N. Mattsson, U. Andreasson, S. Persson, et al., CSF biomarker variability in the Alzheimer's Association quality control program, Alzheimers Dement. 9 (2013) 251-261.
55. N. Mattsson, E. Rosén, O. Hansson, et al., Age and diagnostic performance of Alzheimer disease CSF biomarkers, Neurology 78 (2012) 68-476.
56. N. Mattsson, H. Zetterberg, K. Blennow, Lessons from multicenter studies on CSF biomarkers for Alzheimer's Disease, Int. J. Alzheimers Dis. (2010).
57. N. Mattsson, H. Zetterberg, O. Hansson, et al., CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment, JAMA 302 (2009) 385-393.
58. G. McKhann, D. Drachman, M. Folstein, R. Katzman, D. Price, E.M. Stadlan, Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease, Neurology 4 (1984) 939-944.
59. G.M. McKhann, M.S. Albert, M. Grossman, B. Miller, D. Dickson, J.Q. Trojanowski, Clinical and pathological diagnosis of frontotemporal dementia: report of the work group on frontotemporal dementia and pick's disease, Arch. Neurol. 58 (2001) 1803-1809.
60. G.M. McKhann, D.S. Knopman, H. Chertkow, et al., The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement. 7 (2011) 263-269.
61. M.-M. Mesulam, Primary progressive aphasia, Ann. Neurol. 49 (2001) 425-432.
62. M.-M. Mesulam, Slowly progressive aphasia without generalized dementia, Ann. Neurol. 11 (1982) 592-598.
63. R.C. Mohs, W.G. Rosen, K.L. Davis, The Alzheimer's Disease assessment scale: an instrument for assessing treatment efficacy, Psychopharmacol. Bull. 19 (1983) 448-450.
64. D. Neary, J. Snowden, D. Mann, Frontotemporal dementia, Lancet Neurol. 4 (2005) 771-780.
65. D. Neary, J.S. Snowden, L. Gustafson, U. Passant, D. Stuss, S. Black, M. Freedman, A. Kertesz, P.H. Robert, M. Albert, K. Boone, B.L. Miller, J. Cummings, D.F. Benson, Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria, Neurology 51 (1998) 1546-1554.
66. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS), Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales, Lancet 357 (2001) 169-175.
67. A. Padovani, E. Premi, A. Pilotto, S. Gazzina, M. Cosseddu, S. Archetti, V. Cancelli, B. Paghera, B. Borroni, Overlap between frontotemporal dementia and Alzheimer's disease: cerebrospinal fluid pattern and neuroimaging study, J. Alzheimers Dis. 36 (2013) 49-55.
68. Y.A.L. Pijnenburg, J.C. Janssen, N.S.M. Schoonenboom, A. Petzold, C. Mulder, T. Stigbrand, N. Norgren, H. Heijst, C.E. Hack, P. Scheltens, C.E. Teunissen, CSF neurofilaments in frontotemporal dementia compared with early onset alzheimer's disease and controls, Dement. Geriatr. Cogn. Disord. 23 (2007) 225-230.
69. Y.A.L. Pijnenburg, S.N.M. Schoonenboom, F. Barkhof, D.L. Knol, C. Mulder, G.J. Van Kamp, J.C. Van Swieten, P. Scheltens, CSF biomarkers in frontotemporal lobar degeneration: relations with clinical characteristics, apolipoprotein E genotype, and neu-roimaging, J. Neurol. Neurosurg. Psychiatry 77 (2006) 246-248.
70. Y.A.L. Pijnenburg, S.N.M. Schoonenboom, P.D. Mehta, S.P. Mehta, C. Mulder, R. Veerhuis, M.A. Blankenstein, P. Scheltens, Decreased cerebrospinal fluid amyloid beta (1-40) levels in frontotemporal lobar degeneration, J. Neurol. Neurosurg. Psychiatry 78 (2007) 735-737.
71. K. Rascovsky, J.R. Hodges, D. Knopman, et al., Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia, Brain 134 (2011) 2456-2477.
72. M. Riemenschneider, S. Wagenpfeil, J. Diehl, N. Lautenschlager, T. Theml, B. Heldmann, A. Drzezga, T. Jahn, H. Förstl, A. Kurz, Tau and Abeta42 protein in CSF of patients with frontotemporal degeneration, Neurology 58 (2002) 1622-1628.
73. W.G. Rosen, R.C. Mohs, K.L. Davis, A new rating scale for Alzheimer's Disease, Am. J. Psychiatry 141 (1984) 1356-1364.
74. S.M. Rosso, E. van Herpen, Y.A.L. Pijnenburg, N.S.M. Schoonenboom, P. Scheltens, P. Heutink, J.C. van Swieten, Total tau and phophorylated tau 181 levels in the cerebro-spinal fluid of patients with frontotemporal dementia due to P301L and G272V tau mutations, Arch. Neurol. 60 (2003) 1209-1213.
75. G.M. Savva, S.B. Wharton, P.G. Ince, G. Forster, F.E. Matthews, C. Brayne, Medical research council cognitive function and ageing study. Age, neuropathology, and dementia, N. Engl. J. Med. 360 (2009) 2302-2309.
76. B.A. Schaffer, L. Bertram, B.L. Miller, K. Mullin, S. Weintraub, N. Johnson, E.H. Bigio, M. Mesulam, M. Wiedau-Pazos, G.R. Jackson, J.L. Cummings, R.M. Cantor, A.I. Levey, R.E. Tanzi, D.H. Geschwind, Association of GSK3B with Alzheimer disease and frontotemporal dementia, Arch. Neurol. 65 (2008) 1368-1374.
77. C.S. Scherling, T. Hall, F. Berisha, K. Klepac, A. Karydas, G. Coppola, J.H. Kramer, G. Rabinovici, M. Ahlijanian, B.L. Miller, W. Seeley, L.T. Grinberg, H. Rosen, J. Meredith, A.L. Boxer, CSF neurofilament concentration reflects disease severity in frontotemporal degeneration, Ann. Neurol. 75 (2014) 116-126.
78. N.S.M. Schoonenboom, F.E. Reesink, N.A. Verwey, M.I. Kester, C.E. Teunissen, P.M. van de Ven, Y.A.L. Pijnenburg, M.A. Blankenstein, A.J. Rozemuller, P. Scheltens, W.M. van der Flier, Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort, Neurology 78 (2012) 47-54.
79. H. Seelaar, J.D. Rohrer, Y.A. Pijnenburg, N.C. Fox, J.C. van Swieten, Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review, J. Neurol. Neurosurg. Psychiatry 82 (2011) 476-486.
80. M. Sjögren, L. Minthon, P. Davidsson, A.K. Granérus, A. Clarberg, H. Vanderstichele, E. Vanmechelen, A. Wallin, K. Blennow, CSF levels of tau, β-amyloid1-42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging, J. Neural Transm. 107 (2000) 563-579.
81. S. Slaets, N. Le Bastard, J.-J. Martin, K. Sleegers, C. Van Broeckhoven, P.P. De Deyn, S. Engelborghs, Cerebrospinal fluid Abeta1-40 improves differential dementia diagnosis in patients with intermediate P-tau181P levels, J. Alzheimers Dis. (2013), http://dx.doi.org/10.3233/JAD-130107.
82. S.A. Small, K. Duff, Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis, Neuron 60 (2008) 534-542.
83. J.S. Snowden, P.J. Goulding, D. Neary, Semantic dementia: a form of circumscribed cerebral atrophy, Behav. Neurol. 2 (1989) 167-182.
84. P.E. Spies, D. Slats, J.M. Sjögren, B.P. Kremer, F.R. Verhey, M.G. Rikkert, M.M. Verbeek, The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia, Curr. Alzheimer Res. 7 (2010) 470-476.
85. K. Stamer, R. Vogel, E. Thies, E. Mandelkow, E.M. Mandelkow, Tau blocks traffic of or-ganelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress, J. Cell Biol. 156 (2002) 1051-1063.
86. H. Struyfs, B. Van Broeck, M. Timmers, E. Fransen, K. Sleegers, C. Van Broeckhoven, P.P. De Deyn, J.R. Streffer, M. Mercken, S. Engelborghs, Diagnostic accuracy of cere-brospinal fluid amyloid-β isoforms for early and differential dementia diagnosis, J. Alzheimers Dis. 45 (2015) 813-822.
87. W. Tang, Q. Huang, Y. Wang, Z.Y. Wang, Y.Y. Yao, Assessment of CSF Aβ42 as an aid to discriminating Alzheimer's disease from other dementias and mild cognitive impairment: a meta-analysis of 50 studies, J. Neurol. Sci. (2014), http://dx.doi.org/10. 1016/j.jns.2014.07.015.
88. W. Tang, Q. Huang, Y.Y. Yao, Y. Wang, Y.L. Wu, Z.Y. Wang, Does CSF p-tau181 help to discriminate Alzheimer's disease from other dementias and mild cognitive impairment? A meta-analysis of the literature, J. Neural Transm. (2014), http://dx.doi. org/10.1007/s00702-014-1226-y.
89. T. Tapiola, I. Alafuzoff, S.K. Herukka, L. Parkkinen, P. Hartikainen, H. Soininen, T. Pirttilä, Cerebrospinal fluid (beta)-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain, Arch. Neurol. 66 (2009) 382-389.
90. T. Lund, M. Groups, Clinical and neuropathological criteria for frontotemporal dementia, J. Neurol. Neurosurg. Psychiatry 57 (1994) 416-418.
91. J.B. Toledo, J. Brettschneider, M. Grossman, S.E. Arnold, W.T. Hu, S.X. Xie, V.M.-L. Lee, L.M. Shaw, J.Q. Trojanowsk, CSF biomarkers cutoffs: the importance of coincident neuropathological diseases, Acta Neuropathol. 124 (2012) 23-35.
92. N.A. Verwey, M.I. Kester, W.M. van der Flier, R. Veerhuis, H. Berkhof, H. Twaalfhoven, M.A. Blankenstein, P. Scheltens, Y.A.L. Pijnenburga, Additional value of CSF amyloid-β40 levels in the differentiation between FTLD and control subjects, J. Alzheimers Dis. 20 (2010) 445-452.
93. N.A. Verwey, R. Veerhuis, H.A.M. Twaalfhoven, D. Wouters, J.J.M. Hoozemans, Y.J.M. Bollen, J. Killestein, M. Bibl, J. Wiltfang, C.E. Hack, P. Scheltens, M.A. Blankenstein, Quantification of amyloid-beta 40 in cerebrospinal fluid, J. Immunol. Methods 348 (2009) 57-66.
94. S.J.B. Vos, C. Xiong, P.J. Visser, M.S. Jasielec, J. Hassenstab, E.A. Grant, N.J. Cairns, J.C. Morris, D.M. Holtzman, A.M. Fagan, Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study, Lancet Neurol. 12 (2013) 957-965.
95. D. Wallon, A. Rovelet-Lecrux, V. Deramecourt, J. Pariente, S. Auriacombe, I. Le Ber, S. Schraen, F. Pasquier, D. Campion, D. Hannequin, Definite behavioral variant of frontotemporal dementia with C9ORF72 expansions despite positive Alzheimer's disease cerebrospinal fluid biomarkers, J. Alzheimers Dis. 32 (2012) 19-22.